Despite this variety of available techniques, a generally accepted consensus as to the most suitable method of assessing MGMT promoter methylation in glioma tissues has not been achieved so far, neither for the requirements of large clinical trials nor for routine diagnostics [10], [22]. Here, MGMT is linked to central nervous system cancer.